TFX Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of -17.18% compared to Teleflex's net margin of 28.41%. Teleflex's return on equity of 1.57% beat Intuitive Surgical's return on equity of 15.6%.

Teleflex has a consensus price target of $165.22, signalling upside risk potential of 25.24%. On the other hand Intuitive Surgical has an analysts' consensus of $622.28 which suggests that it could grow by 37.8%. Given that Intuitive Surgical has higher upside potential than Teleflex, analysts believe Intuitive Surgical is more attractive than Teleflex.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.03%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than Intuitive Surgical quarterly revenues of $2.4B. Teleflex's net income of -$136.7M is lower than Intuitive Surgical's net income of $685.7M. Notably, Teleflex's price-to-earnings ratio is 92.91x while Intuitive Surgical's PE ratio is 70.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.04x versus 19.57x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of -17.18% compared to Teleflex's net margin of 20.07%. Teleflex's return on equity of 1.57% beat LeMaitre Vascular's return on equity of 13.81%.

Teleflex has a consensus price target of $165.22, signalling upside risk potential of 25.24%. On the other hand LeMaitre Vascular has an analysts' consensus of $105.63 which suggests that it could grow by 32.4%. Given that LeMaitre Vascular has higher upside potential than Teleflex, analysts believe LeMaitre Vascular is more attractive than Teleflex.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.293%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.03%. LeMaitre Vascular offers a yield of 0.85% to investors and pays a quarterly dividend of $0.20 per share. Teleflex pays 91.2% of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than LeMaitre Vascular quarterly revenues of $55.7M. Teleflex's net income of -$136.7M is lower than LeMaitre Vascular's net income of $11.2M. Notably, Teleflex's price-to-earnings ratio is 92.91x while LeMaitre Vascular's PE ratio is 41.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.04x versus 8.26x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -17.18% compared to Teleflex's net margin of 26.88%. Teleflex's return on equity of 1.57% beat ResMed's return on equity of 25.56%.

Teleflex has a consensus price target of $165.22, signalling upside risk potential of 25.24%. On the other hand ResMed has an analysts' consensus of $269.42 which suggests that it could grow by 31.32%. Given that ResMed has higher upside potential than Teleflex, analysts believe ResMed is more attractive than Teleflex.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.03%. ResMed offers a yield of 1.01% to investors and pays a quarterly dividend of $0.53 per share. Teleflex pays 91.2% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are smaller than ResMed quarterly revenues of $1.3B. Teleflex's net income of -$136.7M is lower than ResMed's net income of $344.6M. Notably, Teleflex's price-to-earnings ratio is 92.91x while ResMed's PE ratio is 24.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.04x versus 6.14x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -17.18% compared to Teleflex's net margin of 17.38%. Teleflex's return on equity of 1.57% beat West Pharmaceutical Services's return on equity of 18.15%.

Teleflex has a consensus price target of $165.22, signalling upside risk potential of 25.24%. On the other hand West Pharmaceutical Services has an analysts' consensus of $285.01 which suggests that it could grow by 40.26%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.

Teleflex has a beta of 1.191, which suggesting that the stock is 19.095% more volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.112%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.03%. West Pharmaceutical Services offers a yield of 0.4% to investors and pays a quarterly dividend of $0.21 per share. Teleflex pays 91.2% of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $795.4M, which are larger than West Pharmaceutical Services quarterly revenues of $748.8M. Teleflex's net income of -$136.7M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Teleflex's price-to-earnings ratio is 92.91x while West Pharmaceutical Services's PE ratio is 30.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 2.04x versus 5.18x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.